All News

A new report released by the American Cancer Society indicates that while the cancer-related death rate was higher among blacks than in whites in 2014, the racial gap could reduce as minority patients increasingly gain access to insurance and subsequent healthcare.

The abortion rate in the United States hit a historic low in 2014 with 2 likely contributing factors: improved access to contraceptives and increased restrictions to abortion services.

During a Public Health Grand Rounds seminar hosted by the CDC on Tuesday, 3 experts from different vantage points within the healthcare system discussed why opioid use disorder presents unique challenges in women and what can be done to address this crisis.

What we're reading, January 18, 2017: GOP senators plan to reveal Obamacare replacement next week; McKesson to pay $150 million to settle claims that it didn't report suspicious opioid orders; and Sylvia Mathews Burwell will go on DC health insurance exchange once she leaves her post.

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

The study found only tobacco use and hypertension were worse on the heart than depression.

The report finds that the House resolution would create an increasingly unstable insurance market, and that fewer insurers would participate.

What we’re reading, January 17, 2017: a newly finalized federal rule eases record sharing of drug abuse treatment between providers; numerous rallies in support of Obamacare draw thousands across the nation; HHS nominee Representative Tom Price allegedly introduced a Congress bill that favored his stock holdings.

Among the 9 new orphan drugs approved by the FDA in 2016 were 3 treatments for rare diseases that, so far, had no approved treatments: Duchenne muscular dystrophy, spinal muscular atrophy, and severe hepatic veno-occlusive disease.

According to a new study, in addition to tumor type, stage, and the presence of comorbidities, patients receiving cisplatin-based treatments might be at an increased risk of venous thromboembolism.

Despite disagreement over the Affordable Care Act, Democrats and Republicans agree on broader issues like the need to move away from fee-for-service and the need to a better job for those with chronic conditions.

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions.

After the Affordable Care Act allowed states to expand Medicaid eligibility for low-income residents, 25 states and the District of Columbia chose to do so by 2014. A team of researchers from Brown University analyzed data from federally funded community health centers and found increased levels of coverage and better care quality for those in Medicaid expansion states.

An experiment by Park Nicollet Health Services to document personalized pain management goals for patients in oncology clinics lowered documented pain, while physician education on cost information helped reduce treatment costs.

What we're reading, January 16, 2017: House follows Senate vote to begin Obamacare repeal process; President-elect Donald Trump teases Obamacare replacement to provide insurance for everyone; and acceptance of aid-in-dying legislation grows.

There are upwards of 408 “dedicated” internet sites that invite consumers to provide feedback on their experiences in physician offices. The lure of these sites for consumers is that they can see what others are saying about specific physicians.

A new study conducted at The University of Texas has found that a majority of federal exchanges do not include National Cancer Institute-designated cancer centers.

Since patients with COPD often have other comorbidities, researchers sought to understand patient adherence to maintenance COPD medications and adherence to treat other chronic conditions.

A new initiative has been launched at the University of North Carolina to create and share tools to fight rare diseases.

The payment reforms introduced in the Medicare Access and CHIP Reauthorization Act make the medical home care model more relevant than ever.

President-elect Donald J. Trump held a news conference in New York Wednesday on a wide range of topics, but a recurring theme was the future of healthcare. Here are 5 things we learned about Trump’s plans for healthcare at Wednesday’s conference.

The study found that, if anything, children with private coverage are being admitted to the hospital too often, raising questions about the allocation of healthcare resources.

This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.

The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

The new definition applies to CGM devices that have FDA approval for dosing decisions. Right now, Dexcom's G5 meets the 5-part test.

What we're reading, January 13, 2017: more states consider contraception laws with Affordable Care Act (ACA) in peril; GOP will speed up timeline to replace ACA; Tom Price will sell his stocks to avoid conflicts.

Research published in the Journal of Oncology Practice has identified high treatment burden among Medicare patients with early-stage non—small cell lung cancer (NSCLC).

The continued segmentation of the US healthcare system has resulted in a majority of spending on behavioral health disorders being attributed to treatment of the physical comorbidities.

Shortly after Cigna announced it would stop covering the name-brand EpiPen, CVS declared it would begin selling a cheaper generic version of the costly epinephrine injector. Earlier in the week, Heather Bresch, CEO of EpiPen manufacturer Mylan, had reflected on the controversy surrounding the device’s price.